Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients
真实世界证据评估在B细胞淋巴瘤患者中，第一个疗程静脉注射利妥昔单抗生物类似药，后续疗程皮下注射利妥昔单抗的安全性
期刊:
影响因子:
doi:10.3390/pharmacy13030083
Almandeel, Tamather; Khan, Mansoor Ahmed; Algethami, Ashwag; Alaboud, Mashael S; Alkathiri, Munirah A; Aseeri, Mohammed; Absi, Ahmed; Almansour, Mubarak; Alotaibi, Abdullah
